Table 3.
Demographics and clinical characteristics of BRVO patients depending on the response to anti-VEGF treatment.
| Responsive (n = 48) | Poor response (n = 6) | P | |||
|---|---|---|---|---|---|
| Systemic factors | Sex (male:female) | 16:32 | 1:5 | 0.407 | |
| Age (years) | 65.96 ± 11.73 | 57.67 ± 8.69 | 0.101 | ||
| Diabetes mellitus | 15 (31.25%) | 3 (50.00%) | 0.358 | ||
| Hypertension | 29 (60.42%) | 3 (50.00%) | 0.624 | ||
| Dyslipidemia | 13 (27.08%) | 3 (50.00%) | 0.246 | ||
| Aqueous humor cytokines (pg/mL) | IL-1β | 0.00 (0.00;0.00) | 0.00 (0.00;0.00) | 0.614 | |
| IL-2 | 0.20 (0.00;5.46) | 19.79 (0.00;34.71) | 0.087 | ||
| IL-6 | 5.52 (3.42;11.52) | 10.67 (9.26;12.86) | 0.308 | ||
| IL-8 | 23.70 (8.73;46.44) | 34.89 (13.08;37.02) | 0.650 | ||
| IL-10 | 0.80 (0.28;1.14) | 0.46 (0.16;1.76) | 0.825 | ||
| IL-17 | 0.00 (0.00;1.30) | 0.48 (0.00;3.32) | 0.408 | ||
| TNF-α | 3.58 (1.91;5.45) | 4.39 (2.53;5.50) | 0.517 | ||
| VEGF | 51.00 (29.98;83.21) | 105.27 (94.33;114.66) | 0.046 | ||
| PlGF | 3.17 (2.13;4.00) | 4.47 (3.65;6.14) | 0.099 | ||
| Ocular factors | Major BRVO | 30 (62.50%) | 5 (83.33%) | 0.314 | |
| Baseline CST (µm) | 397.5 (328.0;504.5) | 595.5 (447.0;634.0) | 0.021 | ||
| Baseline SFCT (µm) | 264.65 ± 37.26 | 272.00 ± 36.49 | 0.650 | ||
| Baseline BCVA (LogMAR) | 0.45 (0.30;0.70) | 0.55 (0.30;0.70) | 0.900 | ||
| OCT findings | Subretinal fluid | 21 (43.75%) | 5 (83.33%) | 0.163 | |
| EZD grade | 0 | 27 (56.25%) | 0 (0%) | 0.027 | |
| 1 | 13 (27.08%) | 3 (50.00%) | |||
| 2 | 8 (16.67%) | 3 (50.00%) | |||
| DRIL | 23 (47.92%) | 3 (50.00%) | 1.000 | ||
Values are expressed as the mean ± SD or median and interquartile range, as appropriate.
BRVO, branch retinal vein occlusion; IL, interleukin; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; PlGF, placental growth factor; CST, central subfield thickness; SFCT, sub-foveal choroidal thickness; BCVA, best-corrected visual acuity; EZD, ellipsoid zone disruption; DRIL Disorganization of retinal inner layers.